HIV response: Lenacapavir approved in Kenya and is set for from nest January
PrEP initiation refers to the process of starting someone on medication to prevent HIV infection before they are exposed to the virus. This typically involves assessing an individual’s risk factors, confirming they are HIV-negative and then prescribing and educating them on the appropriate PrEP regimen.
World at a crossroads as Africa is called to action in fight against HIV after US paused humanitarian support to developing nations
Much of the discussion at IAS 2025 focused on political will. With international funding under pressure – most notably, cuts to US HIV funding in early 2025 – African governments are being urged to lead with urgency. One of the most sobering realities of IAS 2025 was the impact of a political decision on the HIV response.
HIV/Aids: Kenya to start administering newly approved Lenacapavir antiretroviral drug in January
Lenacapavir received approval from the US Food and Drug Administration (FDA) in June 2025 and has been subsequently endorsed in the updated World Health Organization (WHO) guidelines on long-acting HIV prevention, released in July 2025.
